This page describs different cancer test that are avaible often without a doctors intervention. If you do not want chemo and the other ridiciouls conventional cancer treatments*, you may also want to avoid having the cancer diagnosis on your medical records.
The tests that are currently available make the dangerious biopsy unecessary. However, conventional treatments still require that a person have a biopsy before they will administer their terrible treatments. Sounds like another good reason to walk away from conventional treatments.
List of Sane Cancer Testing
- AMAS for Early Detection, just below.
- HCG Hormone test from two labs
- CA Profile $382
- CA 125 to monitor ovarian cancers
- CA 15.3 for breast cancer
- CA 19.9 to monitor gastrointestinal, pancreatic, liver, and colorectal malignancies
- Progensa urine test for prostate cancer.
AMAS for Early Detection
The antimalignin antibody test, (AMAS) is now available for only $165. The clinical trials using over 4000 patients were completed in 1994, and showed that AMAS is 95% accurate on the first test, and 99% when repeated. The follow-up test is $165 (2009 prices).
The test examines a sample of blood looking for anti-malignin, an antibody that acts against the inner protein layer of a cancer cell, called malignin. However, malignin is not present in an advanced tumor. Therefore, if the test says you have cancer, it is very accurate. If the test says you do not have cancer, you might have a tumor that is in an advanced stage. This test is also useful for monitoring a patient's status in remission. Although not as fast as people would like, the antimalignin antibody levels return to normal in two to three months if treatment is successful. If you obtain a AMAS test early in your treatment, you can use that level to determine if you are making progress, but you will need a few months of treatment before the level will show a result.
You can visit the Oncolab Inc web site or your doctor can call: Oncolab in Boston, (617) 536-3030. I would like to thank Dianne Jacobs Thompson of Truth Quest 2** for bringing this information to my attention.
HCG Hormone Test
This test measures the presence of the human chorionic gonadotrophic (HCG) hormone. If a person is either pregnant, has a serious injury, or has cancer, an HCG test would be positive. The appearance of HCG at the site of a serious injury is due to the fact that trophoblast cells are being used in the healing process. They should be turned off after healing is nearly finished. The failure to turn off is the cause of cancer in many cases. This is the Beard theory of cancer described below.
The HCG test is a broad-spectrum tumor marker that can be elevated in all malignancies regardless of site. This hormone can be present in men and women in developing cancers several years proior to diagnosis.
Obtaining a HCG Test
Two companies offer this test: Navarro Medical Clinic in Manila, Philippines and American Metabolic Testing, Hollywood, Florida. Both charge about $60.
Navarro Medical Clinic HCG Test
For the test preparation procedure, go to this page*.
American Metabolic Testing HCG Test
Tests for all molecular species of the HCG hormone. However, no test exists for the ALPHA subunit of HCG. This may be the reason for the ocational negative test result in an established cancer patient. Two different, super-sensitive testes are used, where one will confirm the other. They claim that, "No other laboratory performs these tests at the sensitivity level that we do. Therefore, do-it yourself pregnancy tests, commercial lab reports, and the Navarro test do not accurately report normals below 5.0mIU/mL. Most cancer patients have HCG levels between 1 and 5. The cut-off point is less than 1.0 and the sensitivity of our immunoradiometric assay (IRMA) is 0.03 mIU/mL. Normal levels are less than 1.0 (less than 1.0 for the super-sensitive IRMA test, and less than 1.1 for the second Bioluminescent test.)"
A battery of blood tests designed to predict your risk of developing cancer (CA) long before detectible symptoms may occur and to determine progress of treatments for cancer patients. If the markers decrease, that is a very good sign of healing. The CA Profile includes intact HCG and HCG-beta, core, and fragments, PHI (phosphohexose isomerase), GGTP (gamma glut amyl transpeptidase) enzymes, CEA (carcinoembryonic antigen), TSH (thyroid stimulating hormone), and DHEA-S (dehydroepiandrosterone). Which are explained below except for HCG which is explained in the previous section.
It is recommended to have this test before, during and after trying a therapy. It included measuring the levels of the following (these tests are available separately or all together for $382):
This is the enzyme that channels cells into anaerobic metabolism, i.e. fermentation. This kind of cellular survival is what cancer cells favor. The more energy generating metabolic pathway is oxidative phosphorilation. This is the pathway normal cells require in the presence of oxygen. Hence, more oxygen is less cancer and less oxygen is more cancer. PHI is called the autocrine motility factor, i.e. malignancy or spread factor. This test costs $90.
This is a broad spectrum cancer marker. It is the carcinoembryonic antigen. It can also be elevated in all sorts of cancers. It is very prevalent in cancers of the breast and may be the colon. Like all the others, it is an independent cancer marker that by itself may or may not score. This test costs $90.
This is the most sensitive test for the liver, however, it may be elevated in diseases of the heart, lungs, and kidneys. It is not a tumor marker. However, it may be elevated in cancer patients as a result of either cancer spread or toxic therapy. This test costs $90.
The thyroid stimulating hormone regulates metabolic rate, i.e. oxygen utilization. A high level, i.e. hypothyroidism, may be a prelude to cancer. Chemotherapy frequently causes this anaerobic condition. This test costs $90.
This is the adrenal anti-stress, pro immunity, longevity hormone. The immune system is impaired without adequate amounts of this hormone. Most if not all cancer patients and those in the process of developing cancer have very low or no DHEA in their blood. This test cost $90.
This test is offered by American Metabolic Testing, Hollywood, FL Phone 954 929-4814.
The following tests are give by American Metabolic Testing, Hollywood, Florida at 954 929-4814
This is a tumor marker for monitoring disease progression in nonmucinous epithelial neoplasms of the ovary. CA 125 is not entirely specific for tumors of the ovary. It may be elevated in benign ovarian tumors. CA 125 is a 220 kD glycoprotein expressed by >80% of nonmucinous ovarian epithelial neoplasms. It is also expressed by other coelomic epithelial derivatives and other gynecologic neoplasms, and those of the pancreas, liver, colon, breast, and lung (in smaller percentages). It can also be detected in pregnancy, tubo-ovarian abscess, endometriosis, and benign teratomas (dermoids). Levels >65 IU/mL are associated with malignancy in greater than 90% of cases with pelvic masses. CA 125 is most useful in monitoring progression or recurrence in cases of known ovarian carcinoma. For this purpose, levels >35 IU/mL may be significant; although a lower level does not replace a second-look operation. About 25% of patients have CA 125 level <35 IU/mL before a second look laparotomy despite the presence of residual tumor. However, some patients with negative second-look procedure reverted to a positive CA 125 within 1 month. Therefore, CA 125 remains a useful tool to follow these patients. $90
A more specific test for breast cancer. The result regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The CA 15-3 assay value should be used in conjunction with information available from clinical evaluation and diagnostic procedure. $90
Used to monitor gastrointestinal, pancreatic, liver, and colorectal malignancies. CA 19-9 is a carbohydrate antigen related to Lewis blood group antigen, has been shown to be elevated in sera of some patients with gastrointestinal tumors. It is helpful in post-therapeutic monitoring to determine the success of therapy or the development of recurrence when used serially. CA 19-9 is positive in 70% to 80% of pancreatic carcinomas, 50% to 60% of gastric cancers, 60% of hepatobiliary cancer, 30% of colorectal cancer, and some lung, breast and prostate cancers. Serum levels may differentiate pancreatic cancer from pancreatitis. The test may also be positive in patients with non-neoplastic disease, particularly inflammatory disease of the bowel, cirrhosis, and autoimmune conditions including rheumatoid arthritis (33%), systemic lupus erythematosus (32%), and scleroderma (33%). $90
An Early Detection Service from GenWay Biotech
You Test You, a San Diego division of GenWay Biotech, provides physicians with information to evaluate cancer. They measure blood for elevated levels of the marker tFFDP which may indicate the presence of cancer of one of these cancers:
A new urine test for prostate cancer became available in Europe in April 2010. It is known as the PCA3 (prostate cancer gene 3) test or Progensa. Progensa was approved by the FDA on 12 Feb 2012. The Progensa test is positive in 90% of prostate cancer patients. Go here to learn more: http://www.pca3.org/public/ **
* The link goes to a different page on this web site, alternativecancer.us
** The link opens a new browser window or tab and goes to a different web site.